U.S. Anti-Diabetes Sales to Double, Top $5 Billion by 2001, Paced by User-Friendlier Products.MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Nov. 3, 1995--U.S. sales of diabetes products will more than double from $2.34 billion in 1994 to $5.64 billion by the year 2001, growing at a 13 percent compound annual rate, projects a new study just released by Frost & Sullivan. Monitoring devices and aids will rise from a 39 percent share of total market revenues in 1994 to 54 percent in 2001 while medications decline in share from 51 to 35 percent in the same period, forecasts the report, U.S. DIABETES PRODUCTS MARKETS: EASE-OF-USE PRODUCTS ALLOW FOR MORE EFFECTIVE DISEASE MANAGEMENT. Insulin delivery systems, meanwhile, represent 7 percent of 1994 market revenues, a figure that will rise to 8.5 percent by 2001 at the same time the clinical laboratory test market dips in share from 3 to 2 percent, says the study. The diabetes product market remains under-penetrated, with only some 50 percent of U.S. diabetes cases even diagnosed, leaving large inherent growth potential. Demographic trends are meanwhile increasing diabetes incidence as the susceptible middle-aged grow much more rapidly than the population as a whole. Recent medical warnings calling for more intensive monitoring intensive monitoring Intensive care The continuous monitoring of Pt vital signs, with electronic hookups to the nursing station; IM encompasses real time measurement of BP and ABGs via arterial lines, pulse oximetry, continuous cardiac monitoring, respiration, and therapy for diabetes, advising all diabetics to monitor themselves daily, are expected to heighten height·en v. height·ened, height·en·ing, height·ens v.tr. 1. To raise or increase the quantity or degree of; intensify. 2. To make high or higher; raise. v.intr. disease awareness and underline underline an animal's ventral profile; the shape of the belly when viewed from the side, e.g. pendulous, pot-belly, tucked up, gaunt. the importance of effective management. Increased frequency of patient blood glucose monitoring blood glucose monitoring Sugar monitoring Lab medicine The periodic testing of serum glucose in Pts known to have DM. See Bedside glucose monitoring, Beta cell implants, Diabetes, Glucometer, Glycosylated hemoglobin, Non-Invasive glucose monitoring. will fuel demand for diabetes products, as will more frequent insulin therapy. Manufacturers are investing to produce smaller, increasingly user-friendly products. Diagnostic and monitoring devices are incorporating enhancements capitalizing on advances in medical research and improving patient convenience. Competitors are racing to bring non-invasive blood glucose monitoring devices to market. Pen devices and insulin cartridges
The insulin delivery system market includes insulin syringes and pumps, injection aids and jet injection devices; the monitoring device and aid market includes blood glucose blood glucose Diabetology The principal sugar produced by the body from food–especially carbohydrates, but also from proteins and fats; glucose is the body's major source of energy, is transported to cells via the circulation and used by cells in the presence meters and test strips, non-invasive blood glucose monitoring devices, diabetes lancing devices, lancets, and urine glucose and ketone ketone (kē`tōn), any of a class of organic compounds that contain the carbonyl group, C=O, and in which the carbonyl group is bonded only to carbon atoms. test strips; the clinical laboratory test market includes blood glucose reagents, glycohemoglobin tests and immunodiagnostic immunodiagnostic pertaining to diagnosis by immune reactions. diabetes tests; medications include insulin, oral antidiabetes agents, insulin reaction Noun 1. insulin reaction - hypoglycemia produced by excessive insulin in the system causing coma insulin shock shock - (pathology) bodily collapse or near collapse caused by inadequate oxygen delivery to the cells; characterized by reduced cardiac output and solutions and glucose supplements. Frost & Sullivan, a subsidiary of Market Intelligence, is an international high-technology research firm specializing in healthcare markets. All Frost & Sullivan reports are based on extensive interviews with marketing and technical experts from selected companies in each market segment. Primary research is validated by thorough analysis of available secondary research. Frost & Sullivan is the leading publisher worldwide of high- technology market research reports. Code: 5070-52 Publication Date: November 1995 Price: $ 2195 CONTACT: Frost & Sullivan Amy Arnell, 415/961-9000 (Mountain View) Kristina Menzefricke, 44 171 730 3438 (London) Nadge Keryhuel, 33 1 4742 9127 (Paris) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion